EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

TPS15 - Dermatology 1

Friday 31 May, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
Abstract Text
D1.266
Acute Urticaria: Symptoms, Causes, and Evaluation of Phenotypes Prone to Chronicity
Abstract Text
D1.264
Children with cutaneous mastocytosis: a single center experiment
Abstract Text
D1.254
Efficacy of TAS5315, a Selective and Potent Bruton's Tyrosine Kinase Inhibitor, in Attenuating IgE-Mediated Biphasic Cutaneous Anaphylaxis in Transgenic Mice
Abstract Text
D1.257
Emulsion containing a new chitosan derivative versus petrolatum in children with mild atopic dermatitis: a randomised controlled trial
Abstract Text
D1.263
Features of chronic spontaneous urticaria in patients with atopic comorbidities: Results from CURE, the chronic urticaria registry
Abstract Text
D1.258
Frequent oil-baths and skin barrier during infancy in the PreventADALL study
Abstract Text
D1.260
Linguistic Adaptation of Urticaria Activity Score Over 7 Days (UAS7) to Latvian: Evaluating Disease Activity in Adult Patients with Chronic Spontaneous Urticaria in Latvia
Abstract Text
D1.259
Predicting Responses to Omalizumab in Antihistamine-Refractory Chronic Urticaria
Abstract Text
D1.261
Real world long-term data effectiveness of rupatadine in chronic urticaria: retrospective, monocentric, observational study
Abstract Text
D1.256
Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies
Abstract Text
D1.265
Schnitzler syndrome: a case report
Abstract Text
D1.267
Severe Atopic Dermatitis and HyperEosinophilic Syndrome in Children Undergoing Dupilumab Treatment: Report of two cases
Abstract Text
D1.262
The PAF inhibitor Rupatadine has a positive influence on clinical and laboratory findings in patients with urticarial vasculitis
Abstract Text
D1.255
The UCARE Study on the Prevalence of Sleep Disorders and Nighttime Bruxism in People with Chronic Urticaria

Chairs

Speakers